Clinical Trial Search

Primary: Cocaine Use Over Time — 0.01; 0.007; -0.01; 0.007 slope (change in prob of coc-pos utox/d) — p=<0.05

Primary: Cocaine Self-administration — 2.5; 4.8 cocaine choices/participant

Primary: The Primary Endpoint is the Actual Number of Subjects That Successfully Achieve Abstinence From Cocaine During the Last Three Weeks of Treatment in the "Pre-qualified…

Primary: Endothelin-1 Levels — 2.15; 2.063; 1.956 pg/ml

Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 0.06; 0.94; 0.75; 0.88 cocaine choices

Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 2.75; 1.38; 1.38; 4.75 cocaine choices

Primary: Functional Connectivity Between Corticolimbic Brain Regions During Acute Social Stress — .011; .012; .043; .0008 Arbitrary units

Primary: Regional Availability of Metabotropic Glutamate Type-5 Receptors (mGluR5) — 36.48; 32.19; 25.67; 22.41 mL*cm^3 — p=0.035

Primary: Cocaine Use Based on Urine Drug Screening — 20.36; 15.57; 22.3; 27.8 number of negative drug screens

Primary: Percent Days Abstinent From Cocaine - Self Report — 72.9; 72.9; 59.3 percentage of days — p=.10

Primary: Three Weeks of Continuous Cocaine Abstinence as Measured by Urine Toxicology and Self Report Based on Time Line Follow Back — 13; 7 participants — p==.05

Primary: the Adult ADHD Rating Scale (AARS) (30% Reduction) — 50 percent of participants

Primary: Mean Percentage of Cocaine-positive Urines Over Course of 12 Week Treatment in Subgroup Achieving Abstinence at Baseline — 31; 28; 47; 35 Mean % of cocaine-positive urines

Primary: Last Three Weeks of Cocaine Abstinence Based on Urine Toxicology Results and Self Reported Use — 7; 18; 30 percentage of participants

Primary: Number of Participants Who Were Cocaine Abstinent as Assessed by Urine Screening (Measure of Treatment Efficacy) — 3; 3; 6 Participants

Primary: Three Weeks of Cocaine Abstinence at End of Study — 9; 0 Participants

Primary: Visual Analog Scale Subjective Rating of Drug Effects — 8.65; 9.85; 13.65; 10.43 units on a scale

Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) - Heart Rate — 7.8; 4.96 beats per minute

Primary: Urine Toxicology Screens — 38.33; 41.85 percentage of cocaine negative urines — p=0.05

Primary: Cocaine Use Determined by Urine Analysis — 62.50; 50.00 percentage of participants no cocaine — p=.4637

Primary: Number of Participants Who Are Cocaine Abstinent During the Last 2 Weeks of Treatment (Weeks 8-9), as Assessed by Urine Test — 0; 4; 2 Participants

Primary: Urine Toxicology for Cocaine. — 84; 68; 56; 67 % cocaine + urines over 2 week blocks

Primary: Change in Cue Reactivity — 126; 18; 16 units on a scale (0-200), high is worse

Primary: The Number of Participants Who Achieved Abstinence From Cocaine During the Last Three Weeks of the Trial — 2; 2 participants — p==0.97

Primary: Cocaine Self-administration — 0; 0; 0; 2.2 Number of doses purchased

Primary: % Urine Samples Negative for Cocaine — .67; .74 percentage of positive urine samples

Primary: Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment — 9.25; 6.09; 6; 4.91 number of…

Primary: Weekly Cocaine Use — 1.1; 1.3 days

Primary: Longest Duration of Abstinence From Cocaine — 4.14; 6.64; 6.93 weeks — p=.01

Primary: Cocaine Safety in Subjects Receiving Donepezil — 0; 2 Participants with an Adverse Event